Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary

February 24, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 37 min

Earnings Call Speaker Segments

Elizabeth Krutoholow

executive
#1

Thanks, Tina. Hello everyone, and welcome to Tempus's conference call covering both Q4 2025 and the entire 2025 fiscal year. Earlier today, Tempus posted its results for the quarter and the year that closed on December 31st, 2025. You can find the press release, a quarter overview, and our newest presentation over on our IR website. With me on the call today from Tempus are Eric Lefkofsky, our founder and CEO, along with Jim Rogers, our CFO. Before we get started, I want to note that management might make forward-looking statements on this call, and those carry risks and uncertainties that may lead actual results to differ materially. To review those risks, please see our Form 10-K and other later filings with the SEC. On this call, we'll also cover non-GAAP financial measures, which aren't prepared under generally accepted accounting principles. You'll find definitions of those non-GAAP financial measures, plus reconciliations to the most directly comparable GAAP financial measures, in our earnings release, which is up on our IR page. At this point, I'd like to hand the call over to Eric.

Eric Lefkofsky

executive
#2

Appreciate that, Liz. For Tempus, 2025 turned out to be a standout year, since both of our businesses expanded quickly and delivered results far beyond what we had anticipated. Revenue for our core business, in total, climbed more than 33%. Once you bring the Ambry acquisition into the picture, clearly it's much higher. Turning to our two primary businesses, let me begin with diagnostics; on the oncology side, units rose 29%, a rate that kept accelerating all through the year. We highlighted that MRD actually grew 56% from one quarter to the next, which is remarkable. Hereditary performed solidly, posting 23% unit growth. Everything within our diagnostic business is speeding up and beating expectations. On the data side, that operation is expanding even more quickly; it really consists of 2 product lines, our licensing business and our applications. Licensing, or Insights, rose 69% during the quarter once you account for the one-time effect of the AstraZeneca warrant, and we expect growth of roughly 40% in the current quarter. Total contract value came in above $1.1 billion and, more importantly, has climbed more quickly than revenue across the last several quarters. Net revenue retention reached 126%, which is remarkably strong given everything; we guided to $1.59 billion, consistent with our 25% long-term growth expectations, along with approximately $65 million in positive adjusted EBITDA. Our balance sheet sits in excellent condition. Our products are connecting with customers. Our AI advantages keep gaining traction, so taken together, we're set up for an outstanding 2026; with that, I'm glad to take your questions.

Callum Titchmarsh

analyst
#3

Yeah, many thanks for taking the question, everyone. Eric, I'd like to pull back from the numbers side of things. I'm sure those will get plenty of attention, so let me widen the lens a little. As you know, there's some nervousness in the markets right now about AI and the way value is being split across that ecosystem, and clearly we're seeing what you'd call the traditional AI names move into healthcare these days. What I'm wondering is how you see your position being defended when it comes to the data. And along those lines, why do you think the big pharma partners you serve, especially on the Insights side, will keep returning for more? The Q1 guide is clearly robust, so I'm watching that closely. Last thing on this: I'd like to know whether what you hear back from those customers indicates they're performing better at their jobs as a result of what you give them. Any flavor of wins you can share and what you're picking up on the ground would be great. Thanks very much.

Eric Lefkofsky

executive
#4

Yeah. I'd say the most compelling business models, in my view, when it comes to AI, especially large language or large multimodal models, are really built on two things: having proprietary data available to train models, and having proprietary distribution once a model is producing insight. As we've discussed before, Tempus holds a unique spot because we possess both of those at scale. We've got more than 450 petabytes of connected multimodal data, and that comes out of our diagnostic business, which delivers real-time insights, a real-time link to outcome and response, can follow patients longitudinally, plus rich molecular data and rich imaging data. This proprietary data set of ours is genuinely one of a kind, and it can be used to train AI, to train models. When we produce Insights or some form of contextualization that we intend to place in a physician's hands, since we're linked to over 5,500 hospitals, since we have more than 8,500 oncologists ordering on a regular basis, plus thousands of additional physicians in other fields, we're able to get those Insights to them in real time within routine clinical care. That's the thing that sets us apart: anyone hoping to copy our data business would need to go out and recreate all of that real-time data, and that's extremely difficult. You'd have to sign contracts with providers, you'd have to obtain the data, you'd have to resolve IT problems, you'd have to organize the data, you'd have to create technology that turns the data into something useful. That's a massive undertaking, and it's the one we've been pursuing for the last 10 years. So because of all that, because of the effort we've put into building the data pipes, harmonizing and structuring the data, and creating technology that sits on top of the data, our offering is simply unique, and nobody else has managed to replicate it. When you consider the size of our data operation, several years back, folks doubted we could reach $100 million in data revenue. Today we're at 4 times that amount, and even at this magnitude, we expect 40% growth. Our net revenue retention stands at 126%, meaning that typically our customers place orders for considerably more each successive year compared to what they purchased the prior year. There are all sorts of evidence points. Our biggest customers keep renewing. Those agreements are getting prolonged. We've made announcements about quite a few of them during the past several years. This happens because we're showing genuine worth, as these customers can leverage our data along with our technology to make smarter decisions regarding which assets to pursue, improve their initial-stage identification of projects, craft smarter phase 2s and phase 3s, enroll the correct groups at the correct moment, and secure approvals for their medications and bring them to market more quickly. That's the reason the data business is sort of experiencing its moment, and the expansion is in fact speeding up.

Subbu Nambi

analyst
#5

Hello, everyone. I appreciate you taking the time to answer my question. During the first quarter, Paige Predict was introduced by your company. Since we've already talked about how you don't anticipate this making a significant contribution to revenue during this year, could you talk about what strategic benefit this additional functionality provides when samples come back as QNS? In the case of xT and xR, how frequently does that happen? One quick thing for Jim. Jim, average selling prices are projected to exceed $2,200 in the years ahead, yet what do you foresee for the 2026 guidance? Many thanks.

Eric Lefkofsky

executive
#6

Okay, let's begin with Paige Predict. I'd really suggest you go through the letter. We attempted to lay several of these points out in what we published; for a long time we've discussed the huge value that comes from contextualizing these diagnostics along with the technology we build around them; it isn't merely about releasing the following iteration of an assay or conducting a study that yields some sort of wet lab enhancement. That alone carries limited weight. When you consider our growth and how robust it is at this scale, a major reason is simply that we possess a technological edge that compels physicians to request our offerings, since those offerings give them richer insights. Among those insights, if you glance at just a handful we highlighted, one is Paige Predict, another is the thing we refer to as our Immune Profile Score, and there are dozens more beyond those. Take Paige Predict: here's an illustration of how we've created technology that, at scale, lets us digitize pathology slides and derive insights from those slides, through which we're able to forecast mutations that are present, which will later appear when next-generation sequencing is performed. The advantage of operating a system in which you're sequencing huge numbers of patients and monitoring mutations, while also digitizing pathology slides and keeping track of them, is that you can start connecting these pieces. Every form of next-generation sequencing carries a certain level of error; that's simply intrinsic to the process of relying on Illumina and other sequencing firms, where sequencing a patient never gives you 100% output. In a certain percentage of cases — a small % — but in a certain percentage of cases, you wind up with results that cannot be delivered back to a physician. Having the ability to digitize a pathology slide and produce Insights, even in instances where sequencing does not succeed, makes our tests somewhat superior to what someone else offers. The additional fact that we can produce those results within hours makes us somewhat quicker at delivering those Insights. It's the same story with our Immune Profile Score; we can examine a great deal of varied multimodal data that we create. That might be digitized pathology slides, it might be transcriptomic data derived from RNA, it might be DNA data, and we sharpen what traditionally have been standard biomarkers, such as tumor mutational burden or other ones. Every one of these Insights we're capable of producing — again, it isn't that any single one by itself is why a physician would choose us, but they simply continue accumulating, and when you look at the foundation model work we're involved in, we believe that will do nothing except speed that up enormously. To whatever degree we are today, say, X% better than another company because we can produce Y% additional Insights, you ought to expect that gap to expand substantially across the coming several years.

James William Rogers

executive
#7

When it comes to the ASP question, Q4 ASPs landed at roughly $1,640, which marked a quarter-over-quarter increase of about $40. As was pointed out in the investor deck and essentially what came up at JPM, we believe there's upside of about $500, or perhaps more than $500, to ASP given the present mix, and that's fueled by a few things. First is xT CDx continuing to shift away from the LDT version toward the FDA-approved version. We've said before that our plan is that by the close of 2026, we'd be exiting with the overwhelming majority of volume on the FDA-approved version. From an ASP standpoint in 2026, that's essentially the largest impact. We also shared that our xF, the liquid biopsy, has been submitted to the FDA. Its ASP effect in 2026 will probably be minimal, though once we reach 2027, it will begin contributing. Finally, commercial payers still offer some upside as we steadily chip away at those; that rounds out the build. Taken together, those three initiatives produce that $500 of upside, with xT CDx serving as the largest driver, and it will unfold across 2026.

Ryan MacDonald

analyst
#8

Thanks for fielding my questions. Eric, you described how the foundation model could dramatically accelerate the stacking initiative and the creation of extra algorithms and modules as time goes on. Could you provide an update on where that foundation model's development currently sits? Last quarter, I believe you said the goal was to have version one of that model finished in Q1 of 2026. Has it gone live yet, and how is it doing versus what you expected? For Jim, regarding the ASPs you just discussed, I'm wondering how you're framing the assumptions underneath volume growth, specifically for oncology and also hereditary, within the 2026 guide? Thanks.

Eric Lefkofsky

executive
#9

I'll go first. There was a deliverable for the foundation model in Q1, requiring us to meet specific benchmarks set by AstraZeneca. We believe every one of those benchmarks has been met, and we've handed all of it over to AZ. Their testing of the model is underway, though we're very pleased with how it performs, so work on this continues. That involved a specific cluster we assembled consisting of slightly more than 1,000 H200s devoted to the oncology foundation model. A second cluster of over 500 GB200 has also been acquired by us. Measured by real compute power, that one exceeds the first cluster. Additional models are being run by us internally, spanning not only oncology but our entire data set, since we hold massive quantities of radiology data, pathology data, cardiology data, neuropsych, and more. We remain extremely bullish on the worth these models will provide, and we're intensifying our commitment to those efforts. Our belief is they'll be catalytic for the diagnostic business too, as we continue embedding insights into our tests, making them smarter and superior to competitors' tests, which ought to speed up growth. These insights are also meant to be spread across our data business so clients receive greater value.

James William Rogers

executive
#10

Right. So regarding the sort of volume estimates beneath the diagnostics segment — well, oncology, like Eric said, grew 29% during Q4. Q1 has gotten off to a solid beginning, so that rate isn't really slowing down as far as we can tell; over on the hereditary side, volumes rose 23% in Q4. Like we've discussed before, the letter points out that we expect this to keep moderating as we lap certain share gains they picked up. There will probably be some unevenness too in hereditary growth rates during 2026. So what the letter highlights is roughly that high teens longer-term growth level. Q1 might come in somewhat under that, then strengthen as the year goes on. Some unevenness is likely, but we still view that high teens figure as reachable. Oncology — once again, our confidence in where that business stands is quite strong. On the hereditary side, once more, we saw some of this deceleration coming, since certain share gains are being lapped.

Mark Massaro

analyst
#11

Hey everyone, nice work on a solid year. I appreciate you taking my questions. In the letter, I believe you mention MRD volumes reached about 4,700 tests during the quarter. I think you referenced that this figure might have been 20 times greater had the whole sales team been selling it. Do I have this right that roughly 5% of your sales force was selling MRD in Q4? Is the correct interpretation that, you know, if all of them sold it, it could be 20x higher in Q4, or was that 20x higher figure more of a goal for the longer term?

Eric Lefkofsky

executive
#12

Okay, look, this is clearly a hypothetical scenario, so there's no way to know what would have occurred in Q1. What we were doing was pointing out the truly extraordinary momentum behind our MRD product, and the key evidence is that we performed 4,700 tests. That represents 56% growth quarter-over-quarter — not year-over-year, but quarter-over-quarter — and we're keeping this initiative heavily restricted. Right now, only a very small fraction of our total sales team is actually selling MRD, and if we allowed every rep to sell it and removed all the restrictions entirely, it could be 20 times higher. Would it actually be that? Well, you only find out once you remove the restrictions, but the point we're making is that the growth is remarkably impressive even with a severely limited sales push. Eventually, we will remove those restrictions on the sales effort. That depends on reimbursement, and it depends on getting the timing right, but our plan is to, over time, ungate this and be fully in the market. You know, other companies with really solid reimbursement — Natera, for instance — took a considerable amount of time to build coverage broadly enough that it made financial sense. We're lucky that we can ungate this in a smart, appropriate way and avoid causing financial havoc. What we're pointing to is this: when you consider our diagnostic platform, which is obviously widely connected for hereditary profiling, widely connected for therapy selection, in both solid tumor profiling and liquid biopsy. When you consider how many EHR connections we have, how many integrations we have, and how many feet we have on the street, deeply embedded within the workflows of such a large percentage of the U.S. oncology market, my guess is that once we ungate this, we'll become a very large MRD supplier.

Jesse Case

analyst
#13

Hello, this is Jesse Case calling in place of Kyle Mikson. We appreciate you answering our questions. If we pull back for a moment and look at oncology, I was hoping you might give us somewhat greater clarity regarding your tests. You mentioned ASP and volume dynamics only briefly, so might you walk us through what the primary growth drivers will be, individually, for xT, xR, xF, xH, and xE across 2026 and afterward? Thanks.

Eric Lefkofsky

executive
#14

Honestly, I'm not sure how to respond to that one. That's a pretty wide-ranging ask, I'd say. In the letter, we point out what I believe is our biggest platform edge, the thing that's really been powering our expansion. That edge — the way we put diagnostics into context, the way we combine clinical information with molecular information, the way we hold such a thorough profile, the insights that come out of having that edge — shows up in xT, our DNA profiling. It shows up in xR, our RNA profiling. It shows up in xA and xF, the liquid biopsies. It shows up in xH, our heme product, and by the way, a whole genome heme product from us launches this year. It shows up in xE, our whole exome product. It runs through the whole platform. It isn't the case that there's one thing pushing DNA and some other thing pushing RNA. The advantage of our core technology is what fuels expansion across all five of those assays.

James William Rogers

executive
#15

One more point I'd make is that the market on its own is expanding too. You know, across the companies we compete with, all of them are seeing fairly healthy rates of growth. It's clear that sequencing is being used more and more by the physicians who place orders and, in the end, by patients. As Eric mentioned, that kind of edge in data is precisely what lets us grab more share of the market.

Eric Lefkofsky

executive
#16

Yeah. When it comes to us, clearly, in solid tumor, growth, well, at this stage, it seems to be happening more quickly than for others.

James William Rogers

executive
#17

Sure, happy to address that.

Casey Woodring

analyst
#18

First, regarding the 2026 outlook, you'd like details on what's baked into the data and services revenue projection. You referenced that a portion of total contract value—specifically $350 million—relates to 2026, so you're asking about how much in-year bookings visibility we have to hit that number and when those bookings would need to land. Then, for a second question, you want the 40% growth assumption for data in the first quarter unpacked—how that breaks down between Insights and trials, and whether any of it comes from the current foundation model work with PathAI and AstraZeneca.

Eric Lefkofsky

executive
#19

During the JPM conference, we mentioned that our bookings have been strong enough that, entering this year, we can see further into how 2026 revenue will take shape than ever before—and not by a small margin. We also noted at JPM that, in a normal case, roughly $100 million of revenue in a year comes from bookings made during that same year—that is, a customer needed data, and we got it to them before the year ended. Since such a large share of our revenue is already locked in for 2026, we expect we'll be doing everything we can to keep the data business's growth in hand, because the drivers behind that growth going into 2026 are just so systemic, and bookings tie directly to revenue; we simply have more than $1.1 billion in the tank. A good chunk of that lands in 2026, we're kicking off the year incredibly strong, and demand for our data products is just insane. It feels like we're in a one-of-a-kind position, pulling farther and farther ahead of everyone else, and that business is simply having a moment. When you look at how the remaining pieces fit together, data licensing makes up the bulk of our data and apps offerings. That's the largest portion by far, so the other components are each fairly modest on their own, though collectively they contribute to that second category. Those include our clinical trial matching operation, TIME, plus our care gap offering known as Next, along with several smaller adjacent products tied to those.

Colleen Kusy

analyst
#20

Hello, and thanks for taking the question. Colleen here, filling in for Doug. You posted clinical oncology volume growth in the high 20s as you came out of 2025. How durable should we consider that volume growth to be as we move through this year and the next one? In what way ought we to think about liquid versus tissue CGP growth across this year? Is there any color you can offer regarding repeat testing with xF, and should we keep assuming that xF represents roughly 25% of total clinical oncology volume moving forward?

James William Rogers

executive
#21

Yeah, I'll kick things off, and then, Eric, feel free to jump in. You know, when it comes to that 29% growth and how it compares, again, as I said earlier, we've gotten off to a solid start here in the Q1, and so, you know, we aren't seeing a huge deceleration in oncology growth rates. Clearly, as you reach bigger and bigger scales, it becomes hard to keep growing at that same pace, but we've gotten off to a solid start. On the breakdown, you know, apart from MRD expanding much more rapidly than the remainder of the portfolio, we're seeing, you know, robust growth in both xT and xF. You know, xF might be expanding a touch quicker than solid, but there isn't, you know, a striking difference there. We aren't seeing sort of that pattern that's been around for quite a while; we aren't seeing much divergence in sort of the product mix, as we look into 2026.

Eric Lefkofsky

executive
#22

Let me tack on a bit here. So our guidance, as it stands, points to 25% growth compared with the prior year. We've flagged that the hereditary side of the business is expanding more slowly. For the full year, our thinking is somewhere in the high teens — mid-to-high teens, roughly that neighborhood. There are a handful of other businesses we've historically identified as also flat. Take, for instance, one we've pulled back from — fairly small, roughly a $20 million CRO operation that we don't devote energy to, that sort of thing. There's a bit of revenue there, or indicate... With Ambry, a meaningful chunk of revenue is rising at a rate well below 25%, which tells you our data business alongside our core oncology diagnostic business are expanding at 30%+ percent, correct? Exactly as we announced publicly, we anticipated roughly 30% growth last year in the core business and wound up at 33, and I'd guess something comparable this year, right? Run the numbers and you'll find we'll be expanding in the neighborhood of 30% plus across those businesses. They're extremely healthy. Liquid is outpacing solid somewhat, and that's been a lasting pattern for us. We don't share detailed splits of each and such, but liquid does grow somewhat faster. Both are extremely healthy; there simply isn't a single factor behind the growth. It isn't the case that repetitive testing, concurrent testing, or any particular kind of testing is driving an outsized effect. What we're seeing is genuinely strong, steady growth. We're seeing genuinely strong liquid growth, marginally better, though that's been a lasting pattern. An increasing number of people want what tumor normal profiling offers. An increasing number of people want what DNA and RNA offer. An increasing number of people want our intelligent connected platform. Our oncology unit growth is simply very robust and shows zero indication of tapering off.

Andrew Brackmann

analyst
#23

Hi everyone. Afternoon. Appreciate you letting us ask. Eric, it's been roughly 12 months now since the Ambry deal wrapped up, and if we look back to the time that purchase was made public, a major piece of the rationale centered on information you'd be capable of producing throughout the whole range of oncology testing. Could you perhaps discuss that deal through that perspective, given that it has now been inside the company for a while, and share what you're observing on that front plus how it has driven expansion in the data side of the business? Thank you.

Eric Lefkofsky

executive
#24

I believe we listed, as you're aware, several rationales for buying Ambry. The very first one, and clearly the biggest, was expanding how comprehensive our testing offerings are. If somebody asked me, "What made you acquire Ambry?" data wouldn't be my answer. My answer would be that the primary motive behind the Ambry purchase was their exceptionally robust hereditary offering. An increasing number of our customers are looking for a complete answer. I think we've mentioned this in the past, you know, I firmly hold the view that eventually, in terms of caring for cancer patients, it will resemble e-commerce buyers, heading to the internet. I don't visit a single e-commerce destination for books, a different one for clothing, and yet another for, you know, gadgets and so forth. I visit Amazon since it essentially carries whatever I require all in a single location, and I'm convinced that will hold true when it comes to sequencing. You know, a growing number of providers are seeking a partner capable of assisting with risk management, assisting with treatment once a diagnosis happens, and assisting with monitoring those individuals after therapy ends. We aim to offer a wide selection. Having said that, we're additionally observing a pattern where an increasing share of our provider allies, and naturally, clearly, to patients' advantage, wish to supply deidentified information to systems such as ours so it can be leveraged to speed up research and to speed up drug discovery and development; this is a massive pattern that I don't expect to end. We continue to have 600,000 individuals annually who lose their lives to cancer. We aren't achieving anywhere near sufficient progress when it comes to wiping that out. I think you're witnessing a shift among institutions that are stating. We must assist in halting the waste, ensuring these patients receive superior drugs and receive them on the market sooner. We view that as an ongoing shift and an advantage derived from the sort of information we gather, and then on a de-identified footing, bring to market.

Dan Brennan

analyst
#25

Great, thank you. Thanks, Dan.

Eric Lefkofsky

executive
#26

Can't hear you.

Dan Brennan

analyst
#27

Apologies for that, Eric. Perhaps just a single question regarding MRD, and one about Insights. Regarding MRD, is there anything new with the first-generation CRC assay? I'm aware it's currently with MolDX. Any details you can share would be helpful. As for the next-generation tumor-naive assay, has there been any conversation among you about the sort of performance benefit you'd anticipate achieving from it? Clearly, you're submitting for two tumor types during this year, and then there are another two that you referenced in the letter. I'm simply curious what degree of performance improvement you believe that might deliver compared with what already exists in the tumor-naive space.

Eric Lefkofsky

executive
#28

Right now, we're going back and forth with MolDX. We didn't specify a timeline for resolution, since MolDX isn't something I have control over. Reimbursement could come together within a month, or it could drag on longer. Honestly, I have no clue. Another reason we didn't highlight it: it simply isn't very significant for the MRD offering we have today, which is roughly 95% tumor-informed. Since we mainly compete using a tumor-informed product alongside Personalis, that accounts for the overwhelming share of where we currently have market penetration. This specific product, which I do believe MolDX will eventually reimburse, won't really shift the needle, because the bar keeps rising. What's going on is that tumor-naive offerings must continually improve to genuinely stay competitive. In CRC, I believe a considerable amount of time will pass before a meaningful share of volume shifts from tumor-informed over to tumor-naive. My view is that the naive market is either episodic or serves patients who, for one reason or another, cannot obtain tissue. Tissue is fairly widespread in colorectal cancer, so I think tumor-informed comes out on top in that subtype for the foreseeable future. Other subtypes exist, such as lung, where tissue is harder to come by, and there I think tumor-naive products can perform very well. We came to see that the initial version of our assay simply wasn't delivering the performance we needed. Rather than, say, running countless studies to gather samples — and I mean countless — we chose to shift direction and start developing the 2nd generation of the assay. Instead of, say, using up those extremely valuable study samples on an older version, we preferred to transition to the newer version, so we pivoted, and we got lucky. Everything we undertake factors in this idea of, say, a comprehensive portfolio, and we were lucky to already have a tumor-naive product that was, you know, performing extremely well commercially, bringing us more volume than we honestly want or need. We didn't need to, say, press too hard on the accelerator for tumor-naive. The 2nd version is progressing nicely, and I expect that eventually we'll have a truly excellent assay on the market.

Mark Schappel

analyst
#29

Eric, as you’re aware, the beginning of a year tends to be the moment when businesses tweak their sales teams and how they bring offerings to market. First off, could you tell us whether you’ve made any significant alterations to the sales organization during this year? And then, to follow up, perhaps you could outline what you see as the company’s main investment priorities over the next year.

Eric Lefkofsky

executive
#30

On the sale side and where our sales team is concerned, nothing major has been done to restructure it. That was clearly handled back in early 2025, and we shared what the effect would be. The positive part is that we are now well past the anniversary of it; as for what we're focused on, nothing has changed: extending the advantages of technology and AI widely into diagnostics and ensuring each choice — be it a choice made in the clinic or one made for research — rests on data. Given how quickly we are expanding and how our business is speeding up, my expectation is that we will keep on the same path.

Brad Bowers

analyst
#31

Hi there. I appreciate you taking my question. I just wanted to dig into the ASP outlook a bit, and perhaps what that means for gross margin. Clearly, there's a lot of potential upside with that $2,200 a test outlook. I was hoping to hear what we ought to expect on the gross margin side. It implies a significant step up. If costs stay where they are and you run the numbers, it moves toward gross margin on the genomic side of 70%+. What could you share regarding that trajectory, and does it track one to one with ASP, or should we be thinking about certain offsets? Thank you.

Eric Lefkofsky

executive
#32

Yeah, I believe whenever ASP goes up, that would naturally result in gross margin going up. We've for a long time tended to take the view that when ASPs rise or when sequencing costs decline, we should revisit how much we enlarge panels in order to produce additional data. Of course, that benefits patients and benefits doctors and so on. We do that roughly once a year. We aren't — since we have these two businesses, diagnostics and data, we depend less on squeezing the most gross profit out of the diagnostics product line than some of our competitors might. With that said, if ASPs go up, we'd expect to see some gross profit improvement, though we're always weighing it to ensure we're delivering the widest panels we can to the market, since that clearly carries a number of downstream consequences.

Elizabeth Krutoholow

executive
#33

I appreciate everyone being here with us right now. We’re eager to bring you another update when the next quarter comes around. Enjoy the rest of your day.

Operator

operator
#34

We appreciate everyone being with us once more. That brings an end to the conference call for today. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.